Addex Therapeutics Statistics
Total Valuation
Addex Therapeutics has a market cap or net worth of CHF 7.24 million. The enterprise value is 5.64 million.
Market Cap | 7.24M |
Enterprise Value | 5.64M |
Important Dates
The next estimated earnings date is Monday, November 11, 2024.
Earnings Date | Nov 11, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
Addex Therapeutics has 98.31 million shares outstanding.
Shares Outstanding | 98.31M |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | n/a |
Owned by Insiders (%) | 18.99% |
Owned by Institutions (%) | 3.97% |
Float | 34.25M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 4.45 |
PB Ratio | n/a |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -0.50 |
EV / Sales | 4.09 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | -0.72 |
Financial Position
The company has a current ratio of 0.71
Current Ratio | 0.71 |
Quick Ratio | 0.40 |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | -0.00 |
Interest Coverage | -495.24 |
Financial Efficiency
Return on equity (ROE) is -809.52% and return on invested capital (ROIC) is -447.02%.
Return on Equity (ROE) | -809.52% |
Return on Assets (ROA) | -125.84% |
Return on Capital (ROIC) | -447.02% |
Revenue Per Employee | 59,997 |
Profits Per Employee | -488,530 |
Employee Count | 23 |
Asset Turnover | 0.26 |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -20.04% in the last 52 weeks. The beta is 1.98, so Addex Therapeutics's price volatility has been higher than the market average.
Beta (5Y) | 1.98 |
52-Week Price Change | -20.04% |
50-Day Moving Average | 0.06 |
200-Day Moving Average | 0.07 |
Relative Strength Index (RSI) | 57.55 |
Average Volume (20 Days) | 652,472 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Addex Therapeutics had revenue of CHF 1.38 million and -11.24 million in losses. Loss per share was -0.13.
Revenue | 1.38M |
Gross Profit | -5.55M |
Operating Income | -10.70M |
Pretax Income | -10.92M |
Net Income | -11.24M |
EBITDA | -10.68M |
EBIT | -10.70M |
Loss Per Share | -0.13 |
Balance Sheet
The company has 1.63 million in cash and 35,185 in debt, giving a net cash position of 1.59 million or 0.02 per share.
Cash & Cash Equivalents | 1.63M |
Total Debt | 35,185 |
Net Cash | 1.59M |
Net Cash Per Share | 0.02 |
Equity (Book Value) | -1.37M |
Book Value Per Share | -0.01 |
Working Capital | -1.36M |
Cash Flow
In the last 12 months, operating cash flow was -7.83 million and capital expenditures -4,373, giving a free cash flow of -7.83 million.
Operating Cash Flow | -7.83M |
Capital Expenditures | -4,373 |
Free Cash Flow | -7.83M |
FCF Per Share | -0.08 |
Margins
Gross Margin | n/a |
Operating Margin | -775.53% |
Pretax Margin | -791.44% |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | -567.54% |
Dividends & Yields
Addex Therapeutics does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | n/a |
Shareholder Yield | n/a |
Earnings Yield | -183.10% |
FCF Yield | -108.24% |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |